Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil is highly toxic to cats and can cause fatal heart issues. Users recommend switching to oral minoxidil to protect pets.

A 22-year-old is using 1mg finasteride daily for hair loss, noting some scalp thickening but still experiencing visible thinning. They are considering oral minoxidil due to concerns about topical application with cats at home, and others in the conversation share positive experiences with oral minoxidil, reporting no side effects and significant hair regrowth.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

This conversation is about a user named "mr_mime125" who experienced results from using topical finasteride (0.1%) and minoxidil (5%) solution 1.5 ml twice a day for the first two months followed by just minoxidil (5%) 1 ml once a day in the last month, resulting in a drastic improvement to their hairline. Other users discussed their progress while asking questions and offering encouragement.

JeremySoCa's DHT level was 29 ng/dl, considered low, and Estradiol was 26.1 pg/dl within the normal range. They are using topical finasteride for hair loss and had a thyroidectomy due to Graves' disease.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The conversation discusses concerns about MVSupplements.com products, specifically the Min+Ru spray and GHK Serum, due to discrepancies in ingredient lists and recent poor feedback. Users also mention a price increase and one user reports no issues with the RU powder.

RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

A user shared their positive experience using Fleava (copper peptides), minoxidil, and micro needling for hair regrowth, noting significant improvement in their hairline. Other users believe the success is primarily due to micro needling and minoxidil.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.

Female (37) experiencing hair loss for 5 years, tried max dose of spiro and oral + topical minox without success. Discovered low cortisol and low DHEA levels, seeking functional medicine practitioner for help.

Minoxidil can inhibit collagen production, potentially causing premature aging. The user is inquiring if Vitamin C serum or derma rolling can counteract this effect.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

The user experienced reduced hair shedding after three months of injecting 1mg BPC-157 into the scalp, while continuing to use dutasteride and minoxidil. The injections are painful, and the user sometimes switches to injecting into the buttocks.

A 29-year-old is using liposomal topical finasteride/minoxidil and low-level light therapy (LLLT) to improve hair growth, showing significant progress in crown recovery. The user prefers liposomal topicals to avoid side effects from oral finasteride and uses the iRestore Essential device for LLLT.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The conversation discusses the use of pyrilutamide for hair loss, specifically its impact on shedding. The user is inquiring if others have experienced increased or decreased shedding after starting pyrilutamide.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.

The conversation discusses concerns about the efficacy of pyrilutamide if left in a mailbox for several hours. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.